Most so-called gold analysts don’t understand the most fundamental fact about gold: It’s not like other investments.
Every few generations…
Gold becomes the only asset investors cannot be without.
That moment is now. I lay it all out for you here – including the four best ways to play the coming gold mania.
Debt is going parabolic as the US added another $1 trillion in debt… in just 71 days.
Confidence in the US dollar is cracking – as other nations dump US Treasuries and buy gold…
And the world is quietly preparing for a monetary reset that will restore gold’s crown as the king of monetary assets – this time, permanently.
The current bull market in gold will be the last one of our lifetime – and the last one you’ll need if you play your cards right.
For those who act before “gold fever” hits, this cycle could lead to complete financial transformation for you and your family. It’s coming.
How do I know?
Because one cutting-edge private company is about to roll out a revolutionary gold investment 5,000 years in the making.
Go here for details before this final gold bull market sees its next leg higher.
Best,
Garrett Goggin, CFA, CMT
Lead Analyst and Founder, Golden Portfolio
A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling
Written by Jeffrey Neal Johnson. Published 11/25/2025.
Key Points
- Revenue growth is driven by increased unit volume, while realized prices have decreased to encourage mass-market adoption.
- The company is securing its competitive advantage by investing heavily in new high-tech manufacturing facilities to meet the global demand for medicines.
- Management has signaled high confidence in the next phase of growth by building significant inventory ahead of the upcoming launch of a daily oral weight-loss pill.
In late November 2025, Eli Lilly and Company (NYSE: LLY) shattered a historic ceiling. The Indianapolis-based drugmaker became the first pharmaceutical company to reach a market capitalization of $1 trillion. This milestone places Lilly in an elite financial weight class previously dominated by technology sector giants.
Historically, pharmaceutical stocks trade at lower valuations than technology companies because investors worry about patent cliffs (when profitable drugs lose protection and face cheaper competition) and regulatory risk.
The $1 deal disappears at midnight. (Ad)
Don't Leave Without Claiming Your $1 Black Friday Deal
Discover how AI can help you trade smarter. One dollar. No commitments.
But Eli Lilly has broken that mold. The stock is trading at a trailing price-to-earnings ratio (P/E) near 70 — a premium typically reserved for high-growth software companies.
Even the forward-looking P/E sits at 45.5, reflecting strong confidence in future earnings.
This valuation points to a shift in market sentiment: investors are valuing Lilly not just for its current drug lineup but as a scalable growth platform. With a beta of just 0.43, the stock has shown materially lower volatility than the broader market, offering an uncommon mix of stability and rapid expansion. The market appears to have repriced metabolic disease management as a foundational utility, akin to cloud computing or smartphones.
Volume Over Price: The New Growth Formula
The primary driver of Lilly's trillion-dollar valuation is its third quarter 2025 earnings results. Total revenue reached $17.6 billion, a 54% increase year over year. While the headline number is striking, investors should focus on how that growth was achieved.
Many drugmakers rely on price increases for revenue gains. Lilly did the opposite. In the third quarter, revenue growth was driven by a 62% increase in sales volume while realized prices fell roughly 10%.
This dynamic is extremely bullish for long-term investors. It shows mass-market adoption instead of price-driven gains. Mounjaro, the company's diabetes treatment, generated $6.52 billion in the quarter — roughly double year-ago sales — while Zepbound, the obesity therapy, contributed $3.59 billion.
The price decrease is strategic: lower prices make reimbursement by insurers and government payers more likely, broadening the user base. This adoption-focused approach mirrors consumer technology rollouts. By prioritizing volume, Lilly builds a more durable revenue stream that is less exposed to political pressure over drug pricing.
Eli Lilly's $50 Billion Moat
In tech, a moat is often an ecosystem; in pharma, it's the ability to scale production at speed.
For the past two years, demand for Lilly's incretin medicines has far outpaced supply. The company couldn't manufacture complex injectable pens quickly enough to meet prescriptions.
To address that, Lilly has committed more than $50 billion to manufacturing expansion since 2020. That includes the LEAP Innovation District in Lebanon, Indiana, and recently announced facilities in Virginia and Texas totaling about $11.5 billion.
Additionally, the company is investing over $1 billion to expand operations in Puerto Rico.
For investors, these capital commitments act as a defensive moat. Competitors may develop similar drugs, but replicating Lilly's manufacturing scale — sterile, high-tech facilities and complex supply chains — takes years and billions of dollars. By securing capacity for complex biologics and small molecules, Lilly protects market share and ensures growth is limited primarily by patient demand.
The Next Catalyst: Moving From Pens to Pills
Injectable pens have driven recent growth, but the next valuation leg depends on a shift to oral medicines. Orforglipron, Lilly's oral GLP-1 daily pill, is central to that transition. Oral delivery removes cold-chain refrigeration needs and eases manufacturing bottlenecks tied to injector pens.
Orforglipron completed Phase 3 trials, showing superiority over oral semaglutide in head-to-head studies. Equally telling is Lilly's balance sheet: Eli Lilly's balance sheet shows $952.3 million capitalized in pre-launch inventory, much of it tied to orforglipron.
That level of pre-launch stocking signals management's confidence in regulatory approval and readiness for a large-scale launch in 2026. A daily pill is easier and cheaper to manufacture and ship worldwide than refrigerated pens. If approved, orforglipron could expand the addressable population into the hundreds of millions, surpassing the reach of current injectables.
Eli Lilly Is More Than a One-Trick Pony
While metabolic medicines grab the headlines, Lilly's premium valuation rests on solid fundamentals that reduce risk. The company's strengths are broader than any single franchise.
First, Lilly has a robust shareholder-return program. Lilly has increased its dividend for 11 consecutive years, now paying $6 per share annually. With a payout ratio near 29%, the dividend appears sustainable and has room to grow.
The board also authorized a $15 billion share repurchase plan in late 2024, signaling management's view that the stock has further upside.
Second, the pipeline is diversified. Data presented at the 2025 American Society of Hematology (ASH) meeting highlighted Jaypirca (pirtobrutinib) in oncology.
The drug is moving into the first-line setting for chronic lymphocytic leukemia, expanding its revenue potential. At the same time, Kisunla (donanemab) for Alzheimer's disease gained approval in the EU and UK, opening new international revenue streams.
Institutional confidence is high: Over 82% of Eli Lilly's stock is held by institutions, and short interest is minimal at 0.68%. That low short interest suggests few sophisticated investors are betting against the company's trajectory.
A New Standard for Healthcare Value
Eli Lilly's climb to a $1 trillion market cap reflects a strategic shift from price-driven to volume-driven growth, backed by expanded manufacturing capacity and a pipeline designed for broad access.
The company raised its full-year 2025 revenue guidance to $63 billion–$63.5 billion, which reinforced investor confidence. While Eli Lilly's stock price is rich by historical pharmaceutical standards, the underlying metrics are persuasive. With projected earnings growth above 32% for the coming year and the potential rollout of oral therapies, Lilly has a clear path for earnings to align with its valuation. The company has effectively turned a medical breakthrough into a consumer staple, offering investors an uncommon mix of healthcare stability and aggressive, tech-style growth.
to bring you the latest market-moving news.
This email is a paid sponsorship from Golden Portfolio, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
Copyright 2006-2025 MarketBeat Media, LLC dba TickerReport.
345 N Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103. United States of America..
0 Response to "Got Gold?"
Post a Comment